Business Standard

Weak Q4 due to lower growth may be rare bitter pill for Sun Pharma

Sun Pharma is in the process of acquiring US-based Taro Pharmaceuticals and taking it private

Sun Pharma
Premium

Devangshu Datta

Listen to This Article

Sun Pharmaceutical Industries reported a 34 per cent year-on-year (Y-o-Y) jump in net profit to Rs 2,654.6 crore in Q4FY24. The company’s Ebitda (earnings before interest, taxes, depreciation, and amortization) was, however, below Street estimates due to lower (but impressive) growth in the Global Specialty Revenues, higher R&D spend, and higher other opex.

This negated a rise in the company’s gross margin. The FY25 guidances may also have disappointed some investors since the stock saw a sell-off.

Sun Pharma surpassed $1 billion in sales in the global specialty segment in FY24, up from $430 million in FY20. Overall, the sales

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 23 2024 | 10:21 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com